Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athersys, Inc. stock logo
ATHX
Athersys
$0.00
$0.01
$1.99
$833K-0.91.77 million shs4 shs
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
$0.00
$0.05
N/A-2.8213,560 shs1,253 shs
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$10.56
+2.5%
$10.12
$9.22
$14.63
$1.27B1.032.16 million shs1.18 million shs
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$24.99
-0.4%
$9.20
$4.30
$13.66
$1.26B1.531.18 million shs29 shs
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
$4.10
$4.10
$1.89
$6.37
$355.05M1.891.16 million shs34.93 million shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athersys, Inc. stock logo
ATHX
Athersys
0.00%0.00%0.00%0.00%-67.74%
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%-90.00%-95.00%-90.00%-99.00%
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
+0.19%+3.83%+0.59%-12.34%-8.44%
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
0.00%+175.00%+175.00%+175.00%+175.00%
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Athersys, Inc. stock logo
ATHX
Athersys
N/AN/AN/AN/AN/AN/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
4.3819 of 5 stars
3.32.00.04.72.01.71.9
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Athersys, Inc. stock logo
ATHX
Athersys
0.00
N/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00
N/AN/AN/A
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
2.50
Moderate Buy$24.00127.27% Upside
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
0.00
N/AN/AN/A
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PGNX, CALA, DVAX, ATHX, and FLXN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $31.00
4/17/2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$12.00 ➝ $10.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Athersys, Inc. stock logo
ATHX
Athersys
$146K0.00N/AN/A($1.33) per share0.00
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/A
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$294.62M4.30$0.16 per share64.86$4.54 per share2.33
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
$85.55M14.70N/AN/A($0.34) per share-73.50
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
$34.99M10.15N/AN/A$0.54 per share7.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Athersys, Inc. stock logo
ATHX
Athersys
-$72.53M-$2.03N/AN/AN/AN/AN/A-223.03%N/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$39.65MN/A0.00N/AN/AN/AN/AN/A
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$27.31M-$0.52N/A21.55N/A-20.39%3.59%2.20%8/5/2025 (Estimated)
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/A
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
-$68.55M-$0.80N/AN/AN/A-180.28%-129.46%-53.23%N/A

Latest PGNX, CALA, DVAX, ATHX, and FLXN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$0.12N/AN/AN/A$87.55 millionN/A
5/6/2025Q1 2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$0.03-$0.11-$0.14-$0.77$70.01 million$68.16 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Athersys, Inc. stock logo
ATHX
Athersys
N/AN/AN/AN/AN/A
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/A
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
N/AN/AN/AN/AN/A
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/AN/AN/AN/AN/A
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Athersys, Inc. stock logo
ATHX
Athersys
N/A
0.06
0.06
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/A
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
0.49
11.93
10.84
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
N/A
4.38
4.05
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
0.99
2.12
2.12
CompanyEmployeesShares OutstandingFree FloatOptionable
Athersys, Inc. stock logo
ATHX
Athersys
2461.72 million61.70 millionNo Data
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
604.87 million4.55 millionNot Optionable
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
350120.08 million116.50 millionOptionable
Flexion Therapeutics, Inc. stock logo
FLXN
Flexion Therapeutics
25750.32 million45.73 millionNo Data
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
7986.60 millionN/AOptionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Athersys stock logo

Athersys NASDAQ:ATHX

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

Calithera Biosciences stock logo

Calithera Biosciences NASDAQ:CALA

$0.0001 0.00 (0.00%)
As of 07/7/2025 12:25 PM Eastern

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Dynavax Technologies stock logo

Dynavax Technologies NASDAQ:DVAX

$10.56 +0.26 (+2.52%)
As of 03:16 PM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Flexion Therapeutics stock logo

Flexion Therapeutics NASDAQ:FLXN

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Progenics Pharmaceuticals stock logo

Progenics Pharmaceuticals NASDAQ:PGNX

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.